Global Multiple Sclerosis Drugs Market Insights, Forecast to 2029

Global Multiple Sclerosis Drugs Market Insights, Forecast to 2029

Table of Contents
1 Study Coverage
1.1 Multiple Sclerosis Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Multiple Sclerosis Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Injectable Medications
1.2.3 Oral Medications
1.2.4 Others
1.3 Market by Application
1.3.1 Global Multiple Sclerosis Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Adults
1.3.3 Children
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Multiple Sclerosis Drugs Sales Estimates and Forecasts 2018-2029
2.2 Global Multiple Sclerosis Drugs Revenue by Region
2.2.1 Global Multiple Sclerosis Drugs Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Multiple Sclerosis Drugs Revenue by Region (2018-2023)
2.2.3 Global Multiple Sclerosis Drugs Revenue by Region (2024-2029)
2.2.4 Global Multiple Sclerosis Drugs Revenue Market Share by Region (2018-2029)
2.3 Global Multiple Sclerosis Drugs Sales Estimates and Forecasts 2018-2029
2.4 Global Multiple Sclerosis Drugs Sales by Region
2.4.1 Global Multiple Sclerosis Drugs Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Multiple Sclerosis Drugs Sales by Region (2018-2023)
2.4.3 Global Multiple Sclerosis Drugs Sales by Region (2024-2029)
2.4.4 Global Multiple Sclerosis Drugs Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Multiple Sclerosis Drugs Sales by Manufacturers
3.1.1 Global Multiple Sclerosis Drugs Sales by Manufacturers (2018-2023)
3.1.2 Global Multiple Sclerosis Drugs Sales Market Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Multiple Sclerosis Drugs in 2022
3.2 Global Multiple Sclerosis Drugs Revenue by Manufacturers
3.2.1 Global Multiple Sclerosis Drugs Revenue by Manufacturers (2018-2023)
3.2.2 Global Multiple Sclerosis Drugs Revenue Market Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Multiple Sclerosis Drugs Revenue in 2022
3.3 Global Key Players of Multiple Sclerosis Drugs, Industry Ranking, 2021 VS 2022 VS 2023
3.4 Global Multiple Sclerosis Drugs Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Multiple Sclerosis Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Multiple Sclerosis Drugs, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Multiple Sclerosis Drugs, Product Offered and Application
3.8 Global Key Manufacturers of Multiple Sclerosis Drugs, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Multiple Sclerosis Drugs Sales by Type
4.1.1 Global Multiple Sclerosis Drugs Historical Sales by Type (2018-2023)
4.1.2 Global Multiple Sclerosis Drugs Forecasted Sales by Type (2024-2029)
4.1.3 Global Multiple Sclerosis Drugs Sales Market Share by Type (2018-2029)
4.2 Global Multiple Sclerosis Drugs Revenue by Type
4.2.1 Global Multiple Sclerosis Drugs Historical Revenue by Type (2018-2023)
4.2.2 Global Multiple Sclerosis Drugs Forecasted Revenue by Type (2024-2029)
4.2.3 Global Multiple Sclerosis Drugs Revenue Market Share by Type (2018-2029)
4.3 Global Multiple Sclerosis Drugs Price by Type
4.3.1 Global Multiple Sclerosis Drugs Price by Type (2018-2023)
4.3.2 Global Multiple Sclerosis Drugs Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Multiple Sclerosis Drugs Sales by Application
5.1.1 Global Multiple Sclerosis Drugs Historical Sales by Application (2018-2023)
5.1.2 Global Multiple Sclerosis Drugs Forecasted Sales by Application (2024-2029)
5.1.3 Global Multiple Sclerosis Drugs Sales Market Share by Application (2018-2029)
5.2 Global Multiple Sclerosis Drugs Revenue by Application
5.2.1 Global Multiple Sclerosis Drugs Historical Revenue by Application (2018-2023)
5.2.2 Global Multiple Sclerosis Drugs Forecasted Revenue by Application (2024-2029)
5.2.3 Global Multiple Sclerosis Drugs Revenue Market Share by Application (2018-2029)
5.3 Global Multiple Sclerosis Drugs Price by Application
5.3.1 Global Multiple Sclerosis Drugs Price by Application (2018-2023)
5.3.2 Global Multiple Sclerosis Drugs Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Multiple Sclerosis Drugs Market Size by Type
6.1.1 US & Canada Multiple Sclerosis Drugs Sales by Type (2018-2029)
6.1.2 US & Canada Multiple Sclerosis Drugs Revenue by Type (2018-2029)
6.2 US & Canada Multiple Sclerosis Drugs Market Size by Application
6.2.1 US & Canada Multiple Sclerosis Drugs Sales by Application (2018-2029)
6.2.2 US & Canada Multiple Sclerosis Drugs Revenue by Application (2018-2029)
6.3 US & Canada Multiple Sclerosis Drugs Market Size by Country
6.3.1 US & Canada Multiple Sclerosis Drugs Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Multiple Sclerosis Drugs Sales by Country (2018-2029)
6.3.3 US & Canada Multiple Sclerosis Drugs Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Multiple Sclerosis Drugs Market Size by Type
7.1.1 Europe Multiple Sclerosis Drugs Sales by Type (2018-2029)
7.1.2 Europe Multiple Sclerosis Drugs Revenue by Type (2018-2029)
7.2 Europe Multiple Sclerosis Drugs Market Size by Application
7.2.1 Europe Multiple Sclerosis Drugs Sales by Application (2018-2029)
7.2.2 Europe Multiple Sclerosis Drugs Revenue by Application (2018-2029)
7.3 Europe Multiple Sclerosis Drugs Market Size by Country
7.3.1 Europe Multiple Sclerosis Drugs Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Multiple Sclerosis Drugs Sales by Country (2018-2029)
7.3.3 Europe Multiple Sclerosis Drugs Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Multiple Sclerosis Drugs Market Size
8.1.1 China Multiple Sclerosis Drugs Sales (2018-2029)
8.1.2 China Multiple Sclerosis Drugs Revenue (2018-2029)
8.2 China Multiple Sclerosis Drugs Market Size by Application
8.2.1 China Multiple Sclerosis Drugs Sales by Application (2018-2029)
8.2.2 China Multiple Sclerosis Drugs Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Multiple Sclerosis Drugs Market Size by Type
9.1.1 Asia Multiple Sclerosis Drugs Sales by Type (2018-2029)
9.1.2 Asia Multiple Sclerosis Drugs Revenue by Type (2018-2029)
9.2 Asia Multiple Sclerosis Drugs Market Size by Application
9.2.1 Asia Multiple Sclerosis Drugs Sales by Application (2018-2029)
9.2.2 Asia Multiple Sclerosis Drugs Revenue by Application (2018-2029)
9.3 Asia Multiple Sclerosis Drugs Sales by Region
9.3.1 Asia Multiple Sclerosis Drugs Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Multiple Sclerosis Drugs Revenue by Region (2018-2029)
9.3.3 Asia Multiple Sclerosis Drugs Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Multiple Sclerosis Drugs Market Size by Type
10.1.1 Middle East, Africa and Latin America Multiple Sclerosis Drugs Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Multiple Sclerosis Drugs Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Multiple Sclerosis Drugs Market Size by Application
10.2.1 Middle East, Africa and Latin America Multiple Sclerosis Drugs Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Multiple Sclerosis Drugs Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Multiple Sclerosis Drugs Sales by Country
10.3.1 Middle East, Africa and Latin America Multiple Sclerosis Drugs Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Multiple Sclerosis Drugs Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Multiple Sclerosis Drugs Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Biogen
11.1.1 Biogen Company Information
11.1.2 Biogen Overview
11.1.3 Biogen Multiple Sclerosis Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.1.4 Biogen Multiple Sclerosis Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Biogen Recent Developments
11.2 Sanofi
11.2.1 Sanofi Company Information
11.2.2 Sanofi Overview
11.2.3 Sanofi Multiple Sclerosis Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.2.4 Sanofi Multiple Sclerosis Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Sanofi Recent Developments
11.3 Novartis
11.3.1 Novartis Company Information
11.3.2 Novartis Overview
11.3.3 Novartis Multiple Sclerosis Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.3.4 Novartis Multiple Sclerosis Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Novartis Recent Developments
11.4 Teva
11.4.1 Teva Company Information
11.4.2 Teva Overview
11.4.3 Teva Multiple Sclerosis Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.4.4 Teva Multiple Sclerosis Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Teva Recent Developments
11.5 Merck KGaA
11.5.1 Merck KGaA Company Information
11.5.2 Merck KGaA Overview
11.5.3 Merck KGaA Multiple Sclerosis Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.5.4 Merck KGaA Multiple Sclerosis Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Merck KGaA Recent Developments
11.6 Bayer
11.6.1 Bayer Company Information
11.6.2 Bayer Overview
11.6.3 Bayer Multiple Sclerosis Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.6.4 Bayer Multiple Sclerosis Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Bayer Recent Developments
11.7 ACORDA
11.7.1 ACORDA Company Information
11.7.2 ACORDA Overview
11.7.3 ACORDA Multiple Sclerosis Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.7.4 ACORDA Multiple Sclerosis Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 ACORDA Recent Developments
11.8 Mallinckrodt
11.8.1 Mallinckrodt Company Information
11.8.2 Mallinckrodt Overview
11.8.3 Mallinckrodt Multiple Sclerosis Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.8.4 Mallinckrodt Multiple Sclerosis Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Mallinckrodt Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Multiple Sclerosis Drugs Industry Chain Analysis
12.2 Multiple Sclerosis Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Multiple Sclerosis Drugs Production Mode & Process
12.4 Multiple Sclerosis Drugs Sales and Marketing
12.4.1 Multiple Sclerosis Drugs Sales Channels
12.4.2 Multiple Sclerosis Drugs Distributors
12.5 Multiple Sclerosis Drugs Customers
13 Market Dynamics
13.1 Multiple Sclerosis Drugs Industry Trends
13.2 Multiple Sclerosis Drugs Market Drivers
13.3 Multiple Sclerosis Drugs Market Challenges
13.4 Multiple Sclerosis Drugs Market Restraints
14 Key Findings in The Global Multiple Sclerosis Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Multiple Sclerosis Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of Injectable Medications
Table 3. Major Manufacturers of Oral Medications
Table 4. Major Manufacturers of Others
Table 5. Global Multiple Sclerosis Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global Multiple Sclerosis Drugs Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 7. Global Multiple Sclerosis Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 8. Global Multiple Sclerosis Drugs Revenue by Region (2024-2029) & (US$ Million)
Table 9. Global Multiple Sclerosis Drugs Revenue Market Share by Region (2018-2023)
Table 10. Global Multiple Sclerosis Drugs Revenue Market Share by Region (2024-2029)
Table 11. Global Multiple Sclerosis Drugs Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 12. Global Multiple Sclerosis Drugs Sales by Region (2018-2023) & (K Units)
Table 13. Global Multiple Sclerosis Drugs Sales by Region (2024-2029) & (K Units)
Table 14. Global Multiple Sclerosis Drugs Sales Market Share by Region (2018-2023)
Table 15. Global Multiple Sclerosis Drugs Sales Market Share by Region (2024-2029)
Table 16. Global Multiple Sclerosis Drugs Sales by Manufacturers (2018-2023) & (K Units)
Table 17. Global Multiple Sclerosis Drugs Sales Share by Manufacturers (2018-2023)
Table 18. Global Multiple Sclerosis Drugs Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 19. Global Multiple Sclerosis Drugs Revenue Share by Manufacturers (2018-2023)
Table 20. Global Key Players of Multiple Sclerosis Drugs, Industry Ranking, 2021 VS 2022 VS 2023
Table 21. Multiple Sclerosis Drugs Price by Manufacturers 2018-2023 (USD/Unit)
Table 22. Global Multiple Sclerosis Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Multiple Sclerosis Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multiple Sclerosis Drugs as of 2022)
Table 24. Global Key Manufacturers of Multiple Sclerosis Drugs, Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Multiple Sclerosis Drugs, Product Offered and Application
Table 26. Global Key Manufacturers of Multiple Sclerosis Drugs, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Multiple Sclerosis Drugs Sales by Type (2018-2023) & (K Units)
Table 29. Global Multiple Sclerosis Drugs Sales by Type (2024-2029) & (K Units)
Table 30. Global Multiple Sclerosis Drugs Sales Share by Type (2018-2023)
Table 31. Global Multiple Sclerosis Drugs Sales Share by Type (2024-2029)
Table 32. Global Multiple Sclerosis Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 33. Global Multiple Sclerosis Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 34. Global Multiple Sclerosis Drugs Revenue Share by Type (2018-2023)
Table 35. Global Multiple Sclerosis Drugs Revenue Share by Type (2024-2029)
Table 36. Multiple Sclerosis Drugs Price by Type (2018-2023) & (USD/Unit)
Table 37. Global Multiple Sclerosis Drugs Price Forecast by Type (2024-2029) & (USD/Unit)
Table 38. Global Multiple Sclerosis Drugs Sales by Application (2018-2023) & (K Units)
Table 39. Global Multiple Sclerosis Drugs Sales by Application (2024-2029) & (K Units)
Table 40. Global Multiple Sclerosis Drugs Sales Share by Application (2018-2023)
Table 41. Global Multiple Sclerosis Drugs Sales Share by Application (2024-2029)
Table 42. Global Multiple Sclerosis Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 43. Global Multiple Sclerosis Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 44. Global Multiple Sclerosis Drugs Revenue Share by Application (2018-2023)
Table 45. Global Multiple Sclerosis Drugs Revenue Share by Application (2024-2029)
Table 46. Multiple Sclerosis Drugs Price by Application (2018-2023) & (USD/Unit)
Table 47. Global Multiple Sclerosis Drugs Price Forecast by Application (2024-2029) & (USD/Unit)
Table 48. US & Canada Multiple Sclerosis Drugs Sales by Type (2018-2023) & (K Units)
Table 49. US & Canada Multiple Sclerosis Drugs Sales by Type (2024-2029) & (K Units)
Table 50. US & Canada Multiple Sclerosis Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 51. US & Canada Multiple Sclerosis Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 52. US & Canada Multiple Sclerosis Drugs Sales by Application (2018-2023) & (K Units)
Table 53. US & Canada Multiple Sclerosis Drugs Sales by Application (2024-2029) & (K Units)
Table 54. US & Canada Multiple Sclerosis Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 55. US & Canada Multiple Sclerosis Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 56. US & Canada Multiple Sclerosis Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 57. US & Canada Multiple Sclerosis Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 58. US & Canada Multiple Sclerosis Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 59. US & Canada Multiple Sclerosis Drugs Sales by Country (2018-2023) & (K Units)
Table 60. US & Canada Multiple Sclerosis Drugs Sales by Country (2024-2029) & (K Units)
Table 61. Europe Multiple Sclerosis Drugs Sales by Type (2018-2023) & (K Units)
Table 62. Europe Multiple Sclerosis Drugs Sales by Type (2024-2029) & (K Units)
Table 63. Europe Multiple Sclerosis Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 64. Europe Multiple Sclerosis Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 65. Europe Multiple Sclerosis Drugs Sales by Application (2018-2023) & (K Units)
Table 66. Europe Multiple Sclerosis Drugs Sales by Application (2024-2029) & (K Units)
Table 67. Europe Multiple Sclerosis Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 68. Europe Multiple Sclerosis Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 69. Europe Multiple Sclerosis Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 70. Europe Multiple Sclerosis Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 71. Europe Multiple Sclerosis Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 72. Europe Multiple Sclerosis Drugs Sales by Country (2018-2023) & (K Units)
Table 73. Europe Multiple Sclerosis Drugs Sales by Country (2024-2029) & (K Units)
Table 74. China Multiple Sclerosis Drugs Sales by Type (2018-2023) & (K Units)
Table 75. China Multiple Sclerosis Drugs Sales by Type (2024-2029) & (K Units)
Table 76. China Multiple Sclerosis Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 77. China Multiple Sclerosis Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 78. China Multiple Sclerosis Drugs Sales by Application (2018-2023) & (K Units)
Table 79. China Multiple Sclerosis Drugs Sales by Application (2024-2029) & (K Units)
Table 80. China Multiple Sclerosis Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 81. China Multiple Sclerosis Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 82. Asia Multiple Sclerosis Drugs Sales by Type (2018-2023) & (K Units)
Table 83. Asia Multiple Sclerosis Drugs Sales by Type (2024-2029) & (K Units)
Table 84. Asia Multiple Sclerosis Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 85. Asia Multiple Sclerosis Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 86. Asia Multiple Sclerosis Drugs Sales by Application (2018-2023) & (K Units)
Table 87. Asia Multiple Sclerosis Drugs Sales by Application (2024-2029) & (K Units)
Table 88. Asia Multiple Sclerosis Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 89. Asia Multiple Sclerosis Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 90. Asia Multiple Sclerosis Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 91. Asia Multiple Sclerosis Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 92. Asia Multiple Sclerosis Drugs Revenue by Region (2024-2029) & (US$ Million)
Table 93. Asia Multiple Sclerosis Drugs Sales by Region (2018-2023) & (K Units)
Table 94. Asia Multiple Sclerosis Drugs Sales by Region (2024-2029) & (K Units)
Table 95. Middle East, Africa and Latin America Multiple Sclerosis Drugs Sales by Type (2018-2023) & (K Units)
Table 96. Middle East, Africa and Latin America Multiple Sclerosis Drugs Sales by Type (2024-2029) & (K Units)
Table 97. Middle East, Africa and Latin America Multiple Sclerosis Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 98. Middle East, Africa and Latin America Multiple Sclerosis Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 99. Middle East, Africa and Latin America Multiple Sclerosis Drugs Sales by Application (2018-2023) & (K Units)
Table 100. Middle East, Africa and Latin America Multiple Sclerosis Drugs Sales by Application (2024-2029) & (K Units)
Table 101. Middle East, Africa and Latin America Multiple Sclerosis Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 102. Middle East, Africa and Latin America Multiple Sclerosis Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 103. Middle East, Africa and Latin America Multiple Sclerosis Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 104. Middle East, Africa and Latin America Multiple Sclerosis Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 105. Middle East, Africa and Latin America Multiple Sclerosis Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 106. Middle East, Africa and Latin America Multiple Sclerosis Drugs Sales by Country (2018-2023) & (K Units)
Table 107. Middle East, Africa and Latin America Multiple Sclerosis Drugs Sales by Country (2024-2029) & (K Units)
Table 108. Biogen Company Information
Table 109. Biogen Description and Major Businesses
Table 110. Biogen Multiple Sclerosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 111. Biogen Multiple Sclerosis Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 112. Biogen Recent Developments
Table 113. Sanofi Company Information
Table 114. Sanofi Description and Major Businesses
Table 115. Sanofi Multiple Sclerosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 116. Sanofi Multiple Sclerosis Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 117. Sanofi Recent Developments
Table 118. Novartis Company Information
Table 119. Novartis Description and Major Businesses
Table 120. Novartis Multiple Sclerosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 121. Novartis Multiple Sclerosis Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 122. Novartis Recent Developments
Table 123. Teva Company Information
Table 124. Teva Description and Major Businesses
Table 125. Teva Multiple Sclerosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 126. Teva Multiple Sclerosis Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 127. Teva Recent Developments
Table 128. Merck KGaA Company Information
Table 129. Merck KGaA Description and Major Businesses
Table 130. Merck KGaA Multiple Sclerosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 131. Merck KGaA Multiple Sclerosis Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 132. Merck KGaA Recent Developments
Table 133. Bayer Company Information
Table 134. Bayer Description and Major Businesses
Table 135. Bayer Multiple Sclerosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 136. Bayer Multiple Sclerosis Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 137. Bayer Recent Developments
Table 138. ACORDA Company Information
Table 139. ACORDA Description and Major Businesses
Table 140. ACORDA Multiple Sclerosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 141. ACORDA Multiple Sclerosis Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 142. ACORDA Recent Developments
Table 143. Mallinckrodt Company Information
Table 144. Mallinckrodt Description and Major Businesses
Table 145. Mallinckrodt Multiple Sclerosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 146. Mallinckrodt Multiple Sclerosis Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 147. Mallinckrodt Recent Developments
Table 148. Key Raw Materials Lists
Table 149. Raw Materials Key Suppliers Lists
Table 150. Multiple Sclerosis Drugs Distributors List
Table 151. Multiple Sclerosis Drugs Customers List
Table 152. Multiple Sclerosis Drugs Market Trends
Table 153. Multiple Sclerosis Drugs Market Drivers
Table 154. Multiple Sclerosis Drugs Market Challenges
Table 155. Multiple Sclerosis Drugs Market Restraints
Table 156. Research Programs/Design for This Report
Table 157. Key Data Information from Secondary Sources
Table 158. Key Data Information from Primary Sources
List of Figures
Figure 1. Multiple Sclerosis Drugs Product Picture
Figure 2. Global Multiple Sclerosis Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Multiple Sclerosis Drugs Market Share by Type in 2022 & 2029
Figure 4. Injectable Medications Product Picture
Figure 5. Oral Medications Product Picture
Figure 6. Others Product Picture
Figure 7. Global Multiple Sclerosis Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 8. Global Multiple Sclerosis Drugs Market Share by Application in 2022 & 2029
Figure 9. Adults
Figure 10. Children
Figure 11. Multiple Sclerosis Drugs Report Years Considered
Figure 12. Global Multiple Sclerosis Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Multiple Sclerosis Drugs Revenue 2018-2029 (US$ Million)
Figure 14. Global Multiple Sclerosis Drugs Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 15. Global Multiple Sclerosis Drugs Revenue Market Share by Region (2018-2029)
Figure 16. Global Multiple Sclerosis Drugs Sales 2018-2029 ((K Units)
Figure 17. Global Multiple Sclerosis Drugs Sales Market Share by Region (2018-2029)
Figure 18. US & Canada Multiple Sclerosis Drugs Sales YoY (2018-2029) & (K Units)
Figure 19. US & Canada Multiple Sclerosis Drugs Revenue YoY (2018-2029) & (US$ Million)
Figure 20. Europe Multiple Sclerosis Drugs Sales YoY (2018-2029) & (K Units)
Figure 21. Europe Multiple Sclerosis Drugs Revenue YoY (2018-2029) & (US$ Million)
Figure 22. China Multiple Sclerosis Drugs Sales YoY (2018-2029) & (K Units)
Figure 23. China Multiple Sclerosis Drugs Revenue YoY (2018-2029) & (US$ Million)
Figure 24. Asia (excluding China) Multiple Sclerosis Drugs Sales YoY (2018-2029) & (K Units)
Figure 25. Asia (excluding China) Multiple Sclerosis Drugs Revenue YoY (2018-2029) & (US$ Million)
Figure 26. Middle East, Africa and Latin America Multiple Sclerosis Drugs Sales YoY (2018-2029) & (K Units)
Figure 27. Middle East, Africa and Latin America Multiple Sclerosis Drugs Revenue YoY (2018-2029) & (US$ Million)
Figure 28. The Multiple Sclerosis Drugs Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 29. The Top 5 and 10 Largest Manufacturers of Multiple Sclerosis Drugs in the World: Market Share by Multiple Sclerosis Drugs Revenue in 2022
Figure 30. Global Multiple Sclerosis Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 31. Global Multiple Sclerosis Drugs Sales Market Share by Type (2018-2029)
Figure 32. Global Multiple Sclerosis Drugs Revenue Market Share by Type (2018-2029)
Figure 33. Global Multiple Sclerosis Drugs Sales Market Share by Application (2018-2029)
Figure 34. Global Multiple Sclerosis Drugs Revenue Market Share by Application (2018-2029)
Figure 35. US & Canada Multiple Sclerosis Drugs Sales Market Share by Type (2018-2029)
Figure 36. US & Canada Multiple Sclerosis Drugs Revenue Market Share by Type (2018-2029)
Figure 37. US & Canada Multiple Sclerosis Drugs Sales Market Share by Application (2018-2029)
Figure 38. US & Canada Multiple Sclerosis Drugs Revenue Market Share by Application (2018-2029)
Figure 39. US & Canada Multiple Sclerosis Drugs Revenue Share by Country (2018-2029)
Figure 40. US & Canada Multiple Sclerosis Drugs Sales Share by Country (2018-2029)
Figure 41. U.S. Multiple Sclerosis Drugs Revenue (2018-2029) & (US$ Million)
Figure 42. Canada Multiple Sclerosis Drugs Revenue (2018-2029) & (US$ Million)
Figure 43. Europe Multiple Sclerosis Drugs Sales Market Share by Type (2018-2029)
Figure 44. Europe Multiple Sclerosis Drugs Revenue Market Share by Type (2018-2029)
Figure 45. Europe Multiple Sclerosis Drugs Sales Market Share by Application (2018-2029)
Figure 46. Europe Multiple Sclerosis Drugs Revenue Market Share by Application (2018-2029)
Figure 47. Europe Multiple Sclerosis Drugs Revenue Share by Country (2018-2029)
Figure 48. Europe Multiple Sclerosis Drugs Sales Share by Country (2018-2029)
Figure 49. Germany Multiple Sclerosis Drugs Revenue (2018-2029) & (US$ Million)
Figure 50. France Multiple Sclerosis Drugs Revenue (2018-2029) & (US$ Million)
Figure 51. U.K. Multiple Sclerosis Drugs Revenue (2018-2029) & (US$ Million)
Figure 52. Italy Multiple Sclerosis Drugs Revenue (2018-2029) & (US$ Million)
Figure 53. Russia Multiple Sclerosis Drugs Revenue (2018-2029) & (US$ Million)
Figure 54. China Multiple Sclerosis Drugs Sales Market Share by Type (2018-2029)
Figure 55. China Multiple Sclerosis Drugs Revenue Market Share by Type (2018-2029)
Figure 56. China Multiple Sclerosis Drugs Sales Market Share by Application (2018-2029)
Figure 57. China Multiple Sclerosis Drugs Revenue Market Share by Application (2018-2029)
Figure 58. Asia Multiple Sclerosis Drugs Sales Market Share by Type (2018-2029)
Figure 59. Asia Multiple Sclerosis Drugs Revenue Market Share by Type (2018-2029)
Figure 60. Asia Multiple Sclerosis Drugs Sales Market Share by Application (2018-2029)
Figure 61. Asia Multiple Sclerosis Drugs Revenue Market Share by Application (2018-2029)
Figure 62. Asia Multiple Sclerosis Drugs Revenue Share by Region (2018-2029)
Figure 63. Asia Multiple Sclerosis Drugs Sales Share by Region (2018-2029)
Figure 64. Japan Multiple Sclerosis Drugs Revenue (2018-2029) & (US$ Million)
Figure 65. South Korea Multiple Sclerosis Drugs Revenue (2018-2029)

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Fingolimod Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 74

The global Fingolimod market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Fingolimod is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Fingolimod is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......

Global Multiple Sclerosis Drugs Market Research Report 2024

Published: 04-Jan-2024        Price: US 2900 Onwards        Pages: 78

The Multiple Sclerosis Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Multiple Sclerosis Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provi......

Global Multiple Sclerosis Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 21-Dec-2023        Price: US 3380 Onwards        Pages: 118

Market Overview of Global Multiple Sclerosis market: According to our latest research, the global Multiple Sclerosis market looks promising in the next 5 years. As of 2022, the global Multiple Sclerosis market was estimated at USD 13809.22 million, and it's anticipated to reach USD 21672.55 million in 2028, with a CAGR of 7.8% during the forecast years. Multiple sclerosis (MS) is a chronic inflammatory neuropathy characterized by demyelination, axonal transection, and neurode......

Fingolimod - Global Market Insights and Sales Trends 2024

Published: 21-Dec-2023        Price: US 3350 Onwards        Pages: 77

The global Fingolimod market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Fingolimod in various end use industries. The expanding demands from the Medical Field, Science Research Field and Other Fields,, are propelling Fingolimod market. Oral, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Inj......

Global Fingolimod Market Research Report 2023, Forecast to 2028

Published: 19-Dec-2023        Price: US 2680 Onwards        Pages: 133

Fingolimod, sold under the brand name Gilenya, is an immunomodulating medication, mostly used for treating multiple sclerosis (MS). Fingolimod is a sphingosine-1-phosphate receptor modulator, which sequesters lymphocytes in lymph nodes, preventing them from contributing to an autoimmune reaction. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) dat......

Global Fingolimod Professional Survey Report 2023, Forecast to 2028

Published: 19-Dec-2023        Price: US 3280 Onwards        Pages: 101

Fingolimod, sold under the brand name Gilenya, is an immunomodulating medication, mostly used for treating multiple sclerosis (MS). Fingolimod is a sphingosine-1-phosphate receptor modulator, which sequesters lymphocytes in lymph nodes, preventing them from contributing to an autoimmune reaction. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) dat......

Multiple Sclerosis Drugs - Global Market Insights and Sales Trends 2024

Published: 19-Dec-2023        Price: US 3350 Onwards        Pages: 96

This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking By Company; 3) comprehensive presentation of the global market for Multiple Sclerosis Drugs, with both qu......

Global Multiple Sclerosis Drugs Market Research Report 2023

Published: 25-Oct-2023        Price: US 2900 Onwards        Pages: 87

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Multiple Sclerosis Drugs market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Biogen - Sanofi - Novartis - Teva - Merck KGaA - Bayer - ACORDA - Mallinckrodt Segment by Type - Injectable......

Global Multiple Sclerosis Drugs Market Insights: Impact of COVID-19 and Future Expectations to 2028

Published: 13-Jun-2023        Price: US 3260 Onwards        Pages: 122

Multiple sclerosis (MS) is the most common disabling neurological disease in young people worldwide. The Multiple Sclerosis Drugs market revenue was 15099.44 Million USD in 2022, and will reach 23584.78 Million USD in 2028, with a CAGR of 7.72% during 2022-2028. This report elaborates the market size, market characteristics, and market growth of the Multiple Sclerosis Drugs industry, and breaks down according to the type, application, and consumption area of Multiple Sclero......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs